Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PPM1B | O75688 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11159892 | 1.00 | PLG (0.41) | PLGPLATLMNAPPM1BPTPN1 | |
| SCHEMBL601771 | 1.00 | PLG (0.41) | PLGPLATLMNAPPM1BPTPN1 | |
| SCHEMBL849072 | 0.89 | PPP5C (0.42) | PLGPLATLMNAEPHX2S1PR5 | |
| SCHEMBL8969589 | 0.89 | PPM1B (0.36) | PLGPLATLMNAPPM1BPTPN1 | |
| SCHEMBL2497591 | 0.87 | EPHX2 (0.47) | EPHX2S1PR5 | |
| SCHEMBL11406200 | 0.85 | S1PR5 (0.46) | EPHX2S1PR5 | |
| SCHEMBL11672195 | 0.85 | S1PR5 (0.46) | EPHX2S1PR5 | |
| SCHEMBL601347 | 0.85 | LMNA (0.45) | PLGPLATLMNAPPM1BPTPN1 | |
| SCHEMBL8453791 | 0.85 | LMNA (0.45) | PLGPLATLMNAPPM1BPTPN1 | |
| SCHEMBL3912901 | 0.83 | SMN1; SMN2 (0.33) | PLGPLATLMNAPPM1BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191088-B1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY & BEDFORD NEW COLLEGE (GB) | 2020-12-16 | — | — | EP | claimed |
| US-10301263-B2 | Anticonvulsant compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2019-05-28 | — | — | US | claimed |
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | claimed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | claimed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | claimed |
| EP-3191088-B1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY & BEDFORD NEW COLLEGE (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-10301263-B2 | Anticonvulsant compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2019-05-28 | — | — | US | disclosed |
| US-20170305859-A1 | An Anticonvulsant Compound | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3191088-A1 | AN ANTICONVULSANT COMPOUND | Royal Holloway And Bedford New College (GB) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016038379-A1 | AN ANTICONVULSANT COMPOUND | ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) | 2016-03-17 | — | — | WO | disclosed |
| EP-1996189-B1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2012-09-26 | — | — | EP | disclosed |
| US-20110207777-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | TELECOM IP LIMITED | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207777-A1 | BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | CHRM1, CHRM2, CHRM4 | PLG 1774/4885PLAT 2965/4885LMNA 2869/4885 |
| US-20170305859-A1 | An Anticonvulsant Compound | PSEN2, BACE2, APP | PLG 1367/4885PLAT 1146/4885LMNA 2224/4885 |
| US-10301263-B2 | Anticonvulsant compound | PSEN2, BACE2, APP | PLG 1351/4885PLAT 1071/4885LMNA 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.